Supernus Pharmaceuticals Inc Earnings

The next earnings date for Supernus Pharmaceuticals Inc is November 11, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Supernus Pharmaceuticals Inc Earnings

Report DateEstimated Earnings Per Share
11/11/2025$0.52

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Supernus Pharmaceuticals Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
08/05/2025---$0.9189.99%
05/06/2025Before Market$0.4414.82%
02/25/2025Before Market$0.555.44%
11/04/2024After Market$0.6956.82%
08/06/2024After Market$0.3616.13%
05/08/2024After Market$0.26-31.58%
02/27/2024After Market$0.8961.82%
11/08/2023After Market$0.24200.00%
08/08/2023After Market$-0.0291.30%
05/09/2023After Market$0.2970.59%
02/28/2023After Market$0.43-36.76%
11/08/2022After Market$0.03-91.67%
08/04/2022After Market$0.14-51.72%
05/09/2022After Market$0.4379.17%
02/28/2022After Market$0.04-83.33%
11/03/2021After Market$0.4073.91%
08/04/2021After Market$0.43115.00%
05/05/2021After Market$0.11-54.17%
02/25/2021After Market$0.579.62%
11/03/2020After Market$0.74146.67%
08/17/2020After Market$0.6554.76%
05/05/2020After Market$0.4042.86%
02/25/2020After Market$0.623.33%
11/05/2019After Market$0.54-10.00%
08/06/2019After Market$0.615.17%
05/07/2019After Market$0.34-27.66%
02/26/2019After Market$0.4877.78%
11/06/2018After Market$0.5226.83%
08/07/2018After Market$0.5732.56%
05/08/2018After Market$0.4948.48%
02/27/2018After Market$0.4462.96%
11/06/2017After Market$0.297.41%
08/02/2017After Market$0.3233.33%
05/09/2017After Market$0.19-13.64%
01/20/2017After Market$0.378.82%
12/13/2016---$0.378.82%
08/02/2016After Market$0.1838.46%
05/03/2016After Market$0.08-11.11%
03/02/2016After Market$0.14133.33%
11/03/2015After Market$0.08300.00%
08/04/2015After Market$0.0350.00%
05/05/2015After Market$0.02300.00%
03/10/2015After Market$0.10183.33%
11/11/2014After Market$0.398.33%
08/11/2014---$0.08153.33%
05/12/2014---$-0.3514.63%
03/12/2014---$-0.3929.09%
11/12/2013---$-0.644.48%
08/13/2013---$-0.5712.31%
05/13/2013---$-0.6015.49%
03/14/2013---$-0.5128.17%
11/07/2012---$-0.5511.29%
08/10/2012---$-0.61-27.08%
06/07/2012---$-0.42---

More About Supernus Pharmaceuticals Inc

Country
USA
Full Time Employees
674

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Supernus Pharmaceuticals Inc Earnings” Can Refer to the Supernus Pharmaceuticals Inc Earnings Date

Some people say “Supernus Pharmaceuticals Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Supernus Pharmaceuticals Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Supernus Pharmaceuticals Inc Stock on the Earnings Date

If you own Supernus Pharmaceuticals Inc stock (SUPN) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Supernus Pharmaceuticals Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Supernus Pharmaceuticals Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Supernus Pharmaceuticals Inc Earnings

You can contact us any time if you would like to ask questions about Supernus Pharmaceuticals Inc earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.